Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 6 of 113, showing 5 Applications out of 564 total, starting on record 26, ending on 30

# Protocol No Study Title Investigator(s) & Site(s)

26.

ECCT/25/07/01   FIH Study of CLY-124
    A Phase 1, Randomized, Placebo-Controlled, Double Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CLY-124 in Healthy Volunteers and Participants with Sickle Cell Disease   
Principal Investigator(s)
1. Bernhards Ogutu
Site(s) in Kenya
1. Strathmore University Medical Center [SUMC], Creates for Research in Therapeutic Sciences (Nairobi City county)
2. Victoria Biomedical Research Institute [VIBRI] (Kisumu county)
 
View

27.

ECCT/25/05/11   Sparkle study site-1406
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Doreen Mutua
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. Ahero Clinical trials Unit (Kisumu county)
3. International Cancer institute (Uasin Gishu county)
4. Kondele Childrens Hospital (Kisumu county)
5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county)
6. Gertrudes Children’s Hospital (Nairobi City county)
 
View

28.

ECCT/25/06/03   ZHR-001
    Physiological and Biomarker Monitoring: Enhancing Vital Signs and Biomarkers Algorithm of Binah.AI in the Kenyan Population   
Principal Investigator(s)
1. Borna Achieng Nyaoke
Site(s) in Kenya
Zuri Health Medical Centre
 
View

29.

ECCT/25/05/08   Floral roll over study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Prof Videlis Nduba
Site(s) in Kenya
1. KEMRI Siaya Clinical Research Annex (Siaya county)
2. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
3. Gertrudes Childrens Hospital (Nairobi City county)
4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
5. KEMRI WALTER REED KERICHO (Kericho county)
6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
7. KEMRI Kondele Children\'s Hospital (Kisumu county)
 
View

30.

ECCT/25/05/07   Floral roll over study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Prof Jessie Githanga
Site(s) in Kenya
1. Gertrudes Childrens Hospital (Nairobi City county)
2. KEMRI Kondele Children\'s Hospital (Kisumu county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
5. KEMRI WALTER REED KERICHO (Kericho county)
6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
7. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
 
View